Cargando…

BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination

Activation of farnesoid X receptor (FXR) by obeticholic acid (OCA) reduces hepatic inflammation and fibrosis in patients with primary biliary cholangitis (PBC), a life-threatening cholestatic liver failure. Inhibition of bromodomain-containing protein 4 (BRD4) also has antiinflammatory, antifibrotic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Hyunkyung, Chen, Jinjing, Hu, Xiangming, Sun, Hao, Wu, Shwu-Yuan, Chiang, Cheng-Ming, Kemper, Byron, Chen, Lin-Feng, Kemper, Jongsook Kim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821603/ https://www.ncbi.nlm.nih.gov/pubmed/33290278 http://dx.doi.org/10.1172/jci.insight.141640

Ejemplares similares

Obesity-induced miR-802 directly targets AMPK and promotes nonalcoholic steatohepatitis in mice
por: Sun, Hao, et al.
Publicado: (2022)

Brd4 modulates diet-induced obesity via PPARγ-dependent Gdf3 expression in adipose tissue macrophages
por: Hu, Xiangming, et al.
Publicado: (2021)

Transcriptional regulation of autophagy by an FXR/CREB axis
por: Seok, Sunmi, et al.
Publicado: (2014)

Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis
por: Byun, Sangwon, et al.
Publicado: (2018)

Critical role of RanBP2-mediated SUMOylation of Small Heterodimer Partner in maintaining bile acid homeostasis
por: Kim, Dong-Hyun, et al.
Publicado: (2016)

MicroRNA regulation of AMPK in nonalcoholic fatty liver disease
por: Sun, Hao, et al.
Publicado: (2023)

Transgenic mice lacking FGF15/19-SHP phosphorylation display altered bile acids and gut bacteria, promoting nonalcoholic fatty liver disease
por: Kim, Young-Chae, et al.
Publicado: (2023)

Liver ChIP-seq analysis in FGF19-treated mice reveals SHP as a global transcriptional partner of SREBP-2
por: Kim, Young-Chae, et al.
Publicado: (2015)

Controlling SIRT1 expression by microRNAs in health and metabolic disease
por: Lee, Jiyoung, et al.
Publicado: (2010)

Post-Translational Modifications of FXR; Implications for Cholestasis and Obesity-Related Disorders
por: Appelman, Monique D., et al.
Publicado: (2021)

Discovery That Theonellasterol a Marine Sponge Sterol Is a Highly Selective FXR Antagonist That Protects against Liver Injury in Cholestasis
por: Renga, Barbara, et al.
Publicado: (2012)

Intestinal FGF15/19 physiologically repress hepatic lipogenesis in the late fed-state by activating SHP and DNMT3A
por: Kim, Young-Chae, et al.
Publicado: (2020)

Feeding activates FGF15‐SHP‐TFEB‐mediated lipophagy in the gut
por: Seok, Sunmi, et al.
Publicado: (2022)

Alterations in the gut microbiota and serum metabolomics of spontaneous cholestasis caused by loss of FXR signal in mice
por: Wei, Shizhang, et al.
Publicado: (2023)

Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis
por: Gomez-Ospina, Natalia, et al.
Publicado: (2016)

Stat3 role in the protective effect of FXR Agonist in parenteral nutrition-associated cholestasis
por: Ghosh, Swati, et al.
Publicado: (2023)

AhR and SHP regulate phosphatidylcholine and S-adenosylmethionine levels in the one-carbon cycle
por: Kim, Young-Chae, et al.
Publicado: (2018)

Polygoni Multiflori Radix interferes with bile acid metabolism homeostasis by inhibiting Fxr transcription, leading to cholestasis
por: Dai, Yihang, et al.
Publicado: (2023)

Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase
por: Byun, Sangwon, et al.
Publicado: (2020)

Administration of antibiotics contributes to cholestasis in pediatric patients with intestinal failure via the alteration of FXR signaling
por: Xiao, Yongtao, et al.
Publicado: (2018)

Cross-Regulation of Protein Stability by p53 and Nuclear Receptor SHP
por: Yang, Zhihong, et al.
Publicado: (2012)

BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis
por: Roberts, Thomas C., et al.
Publicado: (2017)

Emodin Rescues Intrahepatic Cholestasis via Stimulating FXR/BSEP Pathway in Promoting the Canalicular Export of Accumulated Bile
por: Xiong, Xiao-Li, et al.
Publicado: (2019)

Curcumin protects ANIT-induced cholestasis through signaling pathway of FXR-regulated bile acid and inflammation
por: Yang, Fan, et al.
Publicado: (2016)

FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis
por: van Golen, Rowan F., et al.
Publicado: (2018)

Correction: Administration of antibiotics contributes to cholestasis in pediatric patients with intestinal failure via the alteration of FXR signaling
por: Xiao, Yongtao, et al.
Publicado: (2022)

Roseburia intestinalis relieves intrahepatic cholestasis of pregnancy through bile acid/FXR-FGF15 in rats
por: Sun, Hanxiang, et al.
Publicado: (2023)

BRD4 regulates cellular senescence in gastric cancer cells via E2F/miR-106b/p21 axis
por: Dong, Xingchen, et al.
Publicado: (2018)

Prolyl isomerase PIN1 regulates the stability, transcriptional activity and oncogenic potential of BRD4
por: Hu, Xiangming, et al.
Publicado: (2017)

Licraside as novel potent FXR agonist for relieving cholestasis: structure-based drug discovery and biological evaluation studies
por: Xi, Lili, et al.
Publicado: (2023)

Discovery of Natural Products as Novel and Potent FXR Antagonists by Virtual Screening
por: Diao, Yanyan, et al.
Publicado: (2018)

Discovery of 9,11-Seco-Cholesterol Derivatives as Novel FXR Antagonists
por: Zhou, Jia-Xu, et al.
Publicado: (2022)

Regulation of programmed cell death by Brd4
por: Hu, Jinfeng, et al.
Publicado: (2022)

Brd4 Is Displaced from HPV Replication Factories as They Expand and Amplify Viral DNA
por: Sakakibara, Nozomi, et al.
Publicado: (2013)

SIRT1 activation synergizes with FXR agonism in hepatoprotection via governing nucleocytoplasmic shuttling and degradation of FXR
por: Cui, Shuang, et al.
Publicado: (2023)

Identification of a mouse Lactobacillus johnsonii strain with deconjugase activity against the FXR antagonist T-β-MCA
por: DiMarzio, Michael, et al.
Publicado: (2017)

Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease
por: Nijmeijer, Rian M., et al.
Publicado: (2011)

Preparation data of the bromodomains BRD3(1), BRD3(2), BRD4(1), and BRPF1B and crystallization of BRD4(1)-inhibitor complexes
por: Hügle, Martin, et al.
Publicado: (2016)

Reconstruction of FXR Beam Conditions
por: Nexsen, W E, et al.
Publicado: (2001)

Structure Optimization of 12β-O-γ-Glutamyl Oleanolic Acid Derivatives Resulting in Potent FXR Antagonist/Modulator for NASH Therapy
por: Ma, Hao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o0e51m26orpj5sp5sv26l1fams